Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
EDITORIAL
Hilka Rauert-Wunderlich
No abstract text is available yet for this article.
November 30, 2023: Blood
#22
JOURNAL ARTICLE
Jennifer Cai, Jennifer Lee
No abstract text is available yet for this article.
November 30, 2023: Blood
#23
JOURNAL ARTICLE
Giby V George, Danielle S Wallace, Ying Wang, John Carney, Murad Elsadawi, W Richard Burack, Andrew G Evans, Paul M Barr, Moises J Velez, Siba El Hussein
No abstract text is available yet for this article.
November 30, 2023: Histopathology
#24
JOURNAL ARTICLE
Zhijuan Zhang, Zheng Ma, Liping Zhang, Kaizhi Zheng, Li Hou
Plasmablastic lymphoma (PBL) is a rare and highly invasive type of non-Hodgkin's lymphoma. It is usually associated with immunosuppression and human immunodeficiency virus infection. PBL most commonly occurs in the oral cavity, lymph nodes, and in other extranodal sites. However, it rarely originates from bilateral sinuses. Herein, we report the case of a 59-year-old man diagnosed with primary PBL of the sinuses confirmed by endoscopic biopsy, imaging materials, histopathological examination, and immunohistochemistry...
November 30, 2023: Ear, Nose, & Throat Journal
#25
JOURNAL ARTICLE
Andrew P Jallouk, Naishu Kui, Ryan Sun, Jason R Westin, Raphael E Steiner, Ranjit Nair, Loretta J Nastoupil, Luis E Fayad, Ajlan Al Zaki, Misha Hawkins, Sherry Adkins, Mansoor Noorani, Kaberi Das, Jared Henderson, Elizabeth J Shpall, Partow Kebriaei, Jeremy Ramdial, Christopher R Flowers, Sattva S Neelapu, Sairah Ahmed, Paolo Strati
Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear. We performed a retrospective analysis of 240 patients with relapsed/refractory large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel (axi-cel) and identified 40 patients (16.7%) who had delay in axi-cel infusion. Of these, 85% had delay due to infection. At time of LDC initiation, patients with delayed infusion had lower absolute neutrophil count (p=0...
November 30, 2023: Haematologica
#26
JOURNAL ARTICLE
Matthew J Maurer, Carla Casulo, Melissa C Larson, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B Cohen, Brad S Kahl, W Richard Burack, Jean L Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C Wei, Ashwini Shewade, Jia Li, James R Cerhan, Brian K Link, Christopher R Flowers
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstrated that mosunetuzumab induced an overall response rate of 80%, complete response rate of 60%, and a median progression-free survival of 17.9 months in patients with relapsed/refractory (r/r) follicular lymphoma (FL) following at least two prior lines of systemic therapy, including alkylator and anti-CD20 antibody-based therapy...
November 30, 2023: Haematologica
#27
JOURNAL ARTICLE
Sylvain Carras, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Sarah Barbieux, Selim Corm, Anne Banos, Ludovic Fouillet, Jehan Dupuis, Margaret Macro, Joel Fleury, Fabrice Jardin, Clementine Sarkozy, Ghandi Damaj, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorvaux, Krimo Bouabdallah, Sandy Amorim, Reda Garidi, Laurent Voillat, Bertrand Joly, Nadine Morineau, Marie Pierre Moles, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Barbara Burroni, Mary Callanan, Steven Le Gouill, Rémy Gressin
Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (Rituximab, Bendamustine, Velcade and Dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients aged over 65. We have now re-examined the classic prognostic factors, adding an assessment of the mutation status of TP53. Patients (n=74; median age 73 years) were treated with the RiBVD combination. Median Progression Free Survival (mPFS) was 79 months, and median Overall Survival (mOS) was 111 months. TP53 mutation status was available for 54/74 (73%) patients...
November 30, 2023: Haematologica
#28
JOURNAL ARTICLE
Karan L Chohan, Radhika Bansal, Matthew A Hathcock, Jonas Paludo, Nora N Bennani, Patrick B Johnston, Arushi Khurana, Urshila Durani, Yucai Wang, Michael W Ruff, Jose C Villasboas Bisneto, Stephen M Ansell, Yi Lin, Saad S Kenderian
No abstract text is available yet for this article.
November 30, 2023: Leukemia & Lymphoma
#29
JOURNAL ARTICLE
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
BACKGROUND: : Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF. METHODS: : This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO)...
November 30, 2023: Blood Research
#30
JOURNAL ARTICLE
Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, XiaoNa Niu, Kai Sun
BACKGROUND: : Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the prognosis of diffuse large B-cell lymphoma (DLBCL). Therefore, this study aimed to investigate the correlation between RPR and the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma. METHODS: : We retrospectively studied 143 patients with newly diagnosed DLBCL and used the median value as the RPR threshold...
November 30, 2023: Blood Research
#31
JOURNAL ARTICLE
Jyoti Kumar, Mark D Ewalt, Yanming Zhang, JinJuan Yao, Meghan C Thompson, Ahmet Dogan
Chronic lymphocytic leukaemia (CLL) is a clonal B-cell malignancy and remains a chronic disease despite improvements in clinical outcomes since the use of targeted therapies. Both clinical and biological parameters are important for determining prognosis. Unlike other mature B-cell lymphomas, translocations involving the immunoglobulin heavy chain (IGH) locus are uncommon in CLL. There have been few case reports of CLL harbouring t(14;18)/IGH::BCL2 and t(14;19)/IGH::BCL3. Here we describe the first two cases of patients with CLL with documented t(14;18)(q32;q21)/IGH::MALT1...
November 29, 2023: British Journal of Haematology
#32
JOURNAL ARTICLE
I N Ismail, A Alaga
INTRODUCTION: Ultrasound guided lung biopsy (USLB) is a minimally invasive diagnostic tool with short examination time and real-time monitoring conducted bedside for accurate diagnosis in order to provide the best treatment. However, it is not widely performed by pulmonologists. We aim to explicate the efficacy and safety of USLB led by pulmonologists. The objective of this study is to assess safety and efficacy of USLB performed by pulmonologists in an outpatient setting. MATERIALS AND METHODS: We retrospectively enrolled patients who underwent the procedure from January 2018 to April 2022...
November 2023: Medical Journal of Malaysia
#33
JOURNAL ARTICLE
Boheng Li, Qidi Zhou, Qin Wan, Xuan Qiao, Shangying Chen, Jianbiao Zhou, Zhijun Wuxiao, Lei Luo, Siok-Bian Ng, Jieping Li, Wee-Joo Chng
BACKGROUND: Overexpressed EZH2 is oncogenically involved in the pathogenesis of different cancerous contexts including extranodal natural killer/T cell lymphoma (ENKTL). However, the underlying mechanisms of EZH2 upregulation have not been fully clarified and it is still difficult to target EZH2 in ENKTL. RESULTS: Current study identifies an E3 ligase TRIP12 that triggers K63-linked polyubiquitination of EZH2 in ENKTL and unexpectedly, stabilizes EZH2. As determined by gene expression profiling (GEP), TRIP12 and EZH2 levels correlate with each other in ENKTL patient samples...
November 29, 2023: Clinical Epigenetics
#34
JOURNAL ARTICLE
Yao Cheng, Xinyan Yang, Lichun Liang, Hua Xin, Xinyu Dong, Weidong Li, Jie Li, Xiaoli Guo, Yue Li, Jian He, Chunbin Zhang, Weiqun Wang
BACKGROUND: CXC chemokine ligand 3 (CXCL3) is a member of CXC-type chemokine family that is identified as a major regulator in immune and inflammation responses. Recently, numerous evidence indicated that CXCL3 is broadly expressed in various human tumor types, and it is also known to play a critical role in mediating tumor development and progression. However, the expression profile of CXCL3 and the exact molecular mechanism behind the role of CXCL3 in colon adenocarcinoma (COAD) has not been fully elucidated...
November 29, 2023: BMC Cancer
#35
JOURNAL ARTICLE
Fei Wang, Silu Cui, Luo Lu, Xiaoliang Shao, Feng Yan, Yaqi Liu, Bai He, Jianfeng Wang, Yang Cao, Yanhua Yue, Yuetao Wang, Weiying Gu
BACKGROUND: 18 F-FDG PET/CT provides precise information about dissemination of lymphoma lesions. Dmax, defined as distance between the two lesions that were farthest apart by PET/CT, was found to be a promising predictor of Diffuse large B-cell lymphoma (DLBCL) outcome in a small size of clinical trial data. We analyzed the impact of Dmax on the outcome of a large real-world DLBCL cohort. METHODS: Data of newly diagnosed DLBCL at the Third Affiliated Hospital of Soochow University were retrospectively collected...
November 29, 2023: BMC Cancer
#36
JOURNAL ARTICLE
Rang Wang, Yue Zhang, Qiuping Fan, Ming Jiang, Liqun Zou, Minggang Su
Interim 18 F-FDG PET/CT (I-PET) has a role in response evaluation and treatment guidance in patients with nasal-type extranodal natural killer/T cell lymphoma (ENKTL). However, there was no agreement on the timing of I-PET performed, after chemotherapy or after chemoradiotherapy. We aimed to find the appropriate timing for I-PET by assessing the prognostic value of I-PET in response evaluation in ENKTL patients. Two hundred and twenty-seven ENKTL patients who had undergone I-PET were retrospectively included...
November 30, 2023: Annals of Hematology
#37
JOURNAL ARTICLE
Gloria Iacoboni, Sascha Dietrich, Nora Liebers
No abstract text is available yet for this article.
December 2023: Lancet Haematology
#38
REVIEW
Peter Dreger, Paolo Corradini, John G Gribben, Bertram Glass, Mats Jerkeman, Marie Jose Kersten, Franck Morschhauser, Alberto Mussetti, Andreas Viardot, Pier Luigi Zinzani, Anna Sureda
The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected salvage algorithms for this condition, and such therapies could have the potential to improve the course of relapsed or refractory LBCL. In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questions regarding eligible histologies; age, comorbidity, and tumour biology restrictions; the handling of very aggressive tumour behaviour; and holding and bridging therapies...
December 2023: Lancet Haematology
#39
JOURNAL ARTICLE
Taichi Hirano, Hiro Tatetsu, Shikiko Ueno, Takafumi Shichijo, Shota Furukawa, Mizuho Tsujihashi, Toshikazu Miyakawa, Shinya Shiraishi, Yusuke Higuchi, Mitsuhiro Uchiba, Jun-Ichirou Yasunaga, Kisato Nosaka, Masao Matsuoka
No abstract text is available yet for this article.
November 30, 2023: Journal of Clinical and Experimental Hematopathology: JCEH
#40
JOURNAL ARTICLE
Shoko Sato, Midori Ishii, Kota Tachibana, Yoshiki Furukawa, Tokuko Toyota, Shintaro Kinoshita, Yoko Azusawa, Jun Ando, Miki Ando
Extranodal NK/T-cell lymphoma, nasal type (ENKL), is characterized by Epstein-Barr virus infection and poor prognosis. We established a novel cell line, ENKL-J1, from bone marrow cells of an ENKL patient. We found that ENKL-J1 cells express ganglioside GD2 and that GD2-directed chimeric antigen receptor T cells exhibit cytotoxicity against ENKL-J1 cells, indicating that GD2 would be a suitable target of GD2-expressing ENKL cells. Targeted next-generation sequencing revealed TP53 and TET2 variants in ENKL-J1 cells...
November 27, 2023: Experimental Hematology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
